Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ponesimod · Ponvory, VSP-128

Small molecule · Modulator of S1P receptor 1 (S1PR1) · developed by Vanda Pharms

Approved FDA, Mar 2021

VNDA Developer

1 Registered trials

What is Ponesimod?

Ponesimod is a sphingosine 1-phosphate receptor 1 modulator that binds S1PR1 with high affinity. It blocks lymphocyte egress from lymph nodes, reducing peripheral blood lymphocytes and lymphocyte migration into the central nervous system.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Ponvory, VSP-128, ACT-128800
Drug type: Small molecule
Targets: S1P receptor 1 (S1PR1)
Mechanism: Modulator of S1P receptor 1 (S1PR1)
Pathways: lymphocyte egress, lymphocyte migration
Therapy area: Gastroenterology
Developer: Vanda Pharms Inc (VNDA)
FDA status: Approved as Ponvory (March 18, 2021), NDA213498 · FDA label
UNII: 5G7AKV2MKP

✅ FDA-approved uses

Relapsing forms of multiple sclerosis

From the indications section of the FDA label (version of Dec 4, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07686081	Phase 3	Ulcerative Colitis (UC)	Recruiting	VNDA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis (UC)

Other drugs acting on S1PR1

Ozanimod FDA approved

More from Vanda Pharms

Iloperidone FDA approved Milsaperidone FDA approved Tasimelteon FDA approved Tradipitant FDA approved Trichostatin A Phase 2 VCA-894A Phase 1/2 VQW-765 Phase 3 VSJ-110 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VNDA page.

Follow VNDA, the company behind Ponesimod

See VNDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VNDA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z